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Abstract
Background: Chronic kidney disease (CKD) is a major threat to the health of people of African ancestry.
We assessed the prevalence and risk factors of CKD among adults in urban Cameroon.
Methods: This was a cross-sectional study of two months duration (March to April 2013) conducted at the Cité des
Palmiers health district in the Littoral region of Cameroon. A multistage cluster sampling approach was applied.
Estimated glomerular filtration rate (eGFR) was based on the Cockcroft-Gault (CG), the four-variable Modification of
Diet in Renal Disease (MDRD) study and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations.
Logistic regression models were used to investigate the predictors of CKD.
Results: In the 500 participants with a mean age of 45.3 ± 13.2 years included, we observed a high prevalence
of overweight and obesity (60.4 %), hypertension (38.6 %) and diabetes (2.8 %). The mean eGFR was 93.7 ± 24.9,
97.8 ± 24.9 and 99.2 ± 31.4 ml/min respectively with the MDRD, CG and CKD-EPI equations. The prevalence of
albuminuria was 7.2 % while the prevalence of decreased GFR (eGFR < 60 ml/min) and CKD (any albuminuria
and/or eGFR < 60 ml/min) was 4.4 and 11 % with MDRD, 5.4 and 14.2 % with CG, and 8.8 and 10 % with CKD-EPI.
In age and sex adjusted logistic regression models, advanced age, known hypertension and diabetes mellitus,
increasing body mass index and overweight/obesity were the predictors of albuminuria, decreased GFR and CKD
according to various estimators.
Conclusion: There is a high prevalence of CKD in urban adults Cameroonian, driven essentially by the commonest
risk factors for CKD.
Background
Sub-Saharan Africa (SSA) countries are undergoing demo-
graphic and epidemiological transition with the double
burden of non-communicable and infectious diseases [1].
The adoption of western lifestyles, mostly in urban areas,
contributes to increase the prevalence of hypertension and
diabetes mellitus in this setting [2–4]. The above factors
are associated with glomerular diseases and constitute the
main etiological factors for chronic kidney disease (CKD)
in SSA [5, 6]. CKD is emerging as one of the major health
threats, affecting 10 % of adults worldwide and contribut-
ing every year to millions of premature deaths [7, 8].
Few studies have been conducted on CKD epidemiology
in SSA [9]. These studies mostly of low methodological
quality have revealed huge disparities in the prevalence of
CKD across SSA regions depending on the definition,
method for assessing glomerular filtration rate (GFR) and
targeted population [4, 9–14].
In central Africa, previous studies have reported a high
prevalence of CKD which affects young adults in their
productive years; being higher in high risk groups such
as people with hypertension, diabetes mellitus, obesity
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or HIV infection [10–12]. The present report presents
findings from a study on the prevalence and risk factors
of CKD in urban Cameroon.
Methods
Study setting and design
We carried a cross-sectional study of two months dur-
ation from March to April 2013 in all health areas of the
Cité des Palmiers health district in the Littoral region of
Cameroon. The Cité des Palmiers health district is the
second largest and populous health district in Douala,
the economic Capital of Cameroon. It comprises eight
health areas with an estimated population of 423,253
inhabitants in 2012. The population is diversified repre-
senting the different ethnic and social groups in the
country, and comprises students, traders, civil servants,
housewives, and low, middle and high income earners
from private sectors. This study was approved by the
Cameroon National Ethics Committee.
We used a multistage cluster sampling to recruit 500
participants as Sumaili et al. in Kinshasa [11], corre-
sponding to 62–63 subjects per health area. Sampling
stages included the health area (first stage), the neigh-
bourhood (second stage) and individuals (third stage).
Adults were informed through community leaders, post-
ers, leaflets and words of mouth, and requested to report
to the chieftainship. All adults who reported on the day
of recruitment benefited from a sensitization campaign,
followed by a random selection of study participants and
data collection.
Data collection
Final year undergraduate medical students collected data
between 8 a.m. to 12 a.m. for participants who provided
a written informed consent. They used a pre-designed
questionnaire to collect socio-demographic data (age,
gender and occupation) and clinical information includ-
ing personal history of existing conditions (hypertension,
diabetes and gout), lifestyle characteristics (alcohol
consumption and smoking), use of nephrotoxic agents
(herbal medicines, foods addictive and street medicines),
anthropometric measurements (weight, height and waist
girth) and blood pressure variables. Blood pressure was
measured according to the World Health Organization
(WHO) guidelines [15] using an automated sphygmo-
manometer (OMRON HEM705CP, Omron Matsusaka
Co, Matsusaka City, Mie-Ken, Japan) on the right arm
with participants in a sitting position. All anthropomet-
ric measurements were performed three times and their
average used in all analyses. In every participant, we
drew 3 ml of whole blood from an antecubital vein into
dry tubes for serum creatinine and collected mid-stream
second morning urine for dipstick tests.
Dipstick tests were performed immediately after sam-
ple collection while blood specimens for serum creatin-
ine were transported on ice-cooled containers to the
biochemistry laboratory of the Douala General Hospital
for processing. Urine dipstick tests were performed with
CombiScreen 7SL PLUS 7 test strips (Analyticon Bio-
technologies AG, D-35104 Lichentenfeis, Germany).
Serum creatinine was measured with a kinetic modifica-
tion of the Jaffé reaction using Human visual spectro-
photometer (Human Gesellschaft, Biochemica und
Diagnostica mbH, Wiesbaden, Germany) and Beckman
creatinine analyzer (Beckman CX systems instruments,
Anaheim, CA, USA). For any participant with positive
dipstick [protein (at least traces), blood, leucocytes)], an-
other urine sample was collected 2 to 3 weeks later to
confirm the results. We excluded 11 (2.2 %) pregnant
women and seven (1.4 %) participants with concomitant
leucocyturia and urine nitrites.
Definitions and calculations
Estimated glomerular filtration rate (eGFR, mL/min)
used the Cockcroft-Gault (CG), the four-variable Modifi-
cation of Diet in Renal Disease (MDRD) study and
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equations [16–18]. CKD was defined by a
confirmed positive dipstick albuminuria (at least traces)
and/or eGFR < 60 ml/min/1.73 m2 according to K/DIGO
guidelines which were used to stage participants for
CKD [19]. eGFR classification was the following: G1
(eGFR ≥ 90); G2 (eGFR 60–89); G3a (eGFR 45–59); G3b
(eGFR 30–44); G4 (eGFR 15–29) and G5 (eGFR < 15).
Albuminuria was classified as: A1 (negative); A2 (trace to
1+) and A3 (at least 2+). Decreased GFR corresponded
to any eGFR < 60 ml/min regardless the equation used.
The following formula was used to convert serum
creatinine from Jaffé reaction (SCrJaffé) to standardized
serum creatinine (SCrStandardized) to be used in MDRD
and CKD-EPI formulas: SCrStandardized = 0.95*SCrJaffé –
0.10 [20, 21]. Hypertension was defined as a systolic
(SBP) ≥140 mmHg and/or a diastolic blood pressure
(DBP) ≥90 mmHg or being on antihypertensive drugs.
Diabetes was defined as self-reported history of doctor
diagnosed condition or use of glucose control agents.
Statistical analysis
Data analysis used SPSS® v.17 software for Windows®
(SPSS Inc., Chicago, USA). We have reported the results
as means and standard deviations, and counts and
percentages. The Fisher exact test, Student t-test and
Mann–Whitney U test were used to compare qualitative
and quantitative variables across subgroups defined by
sex, status for albuminuria, decreased GFR and CKD
according to different GFR estimators. Age and sex ad-
justed logistic regression models were used to investigate
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the predictors of CKD. A p-value <0.05 was used to indi-
cate statistically significant results.
Results
Baseline characteristics of the study population
The mean age was 45.3 years, similarly between men
and women (p = 0.267), Table 1. Alcohol (68.9 vs.
37.8 %), tobacco use (12.7 vs. 0.4 %), and systolic blood
pressure (137 vs. 128 mmHg) were higher in men com-
pared to women (all p < 0.001). However, compared with
men, women were more likely to have a history of
hypertension (15.5 vs. 9.4 %, p = 0.041), to have high
body mass index (BMI, 28.6 vs. 25.8 kg/m2, p < 0.001)),
and to be overweight or obese (68.2 vs. 53.6 %, p =
0.001), Table 1. We observed a higher prevalence of
CKD risk factors including hypertension (38.6 %), over-
weight and obesity (60.4 %), and longstanding use of
herbal (57.8 %) and street (29.6 %) medicines in the
study sample. As expected, serum creatinine was higher
in men than women (p < 0.001) but women had a signifi-
cantly higher mean estimated creatinine clearance by the
CKD-EPI equation (103.5 vs. 95.5 ml/min, p = 0.005).
Furthermore, estimated creatinine clearance was highest
with CKD-EPI equation and lowest with the MDRD
equation.
Staging of kidney function and prevalence of chronic
kidney disease
The staging of kidney function according to various
estimators is presented in Table 1. In general, there was
no sex difference in the staging of kidney function,
regardless of the estimator (all p > 0.206). None of the
participants was in stage G5 regardless of the estimators
used. Similar proportions of stages G3b and G4 were
observed with CKD-EPI and MDRD estimators. The
prevalence of albuminuria was 7.2 % while the preva-
lence of decreased GFR (eGFR < 60 ml/min) was 4.4, 5.4
and 8.8 % respectively based on GFR estimated from the
CKD-EPI, MDRD and CG equations (Table 2). The
prevalence of CKD (any albuminuria and/or eGFR <
60 ml/min) was 10.0, 11.0 and 14.2 % respectively for
CKD-EPI, MDRD and CG equations (Table 3).
Correlates of albuminuria, decreased GFR and CKD
The distribution of baseline characteristics according to
the presence of albuminuria, decreased GFR or CKD is
shown in Tables 2 and 3. Advanced age and known
hypertension and diabetes status were significantly asso-
ciated with albuminuria, decreased GFR and CKD re-
gardless the equation used meanwhile any hypertension
was associated with decreased GFR and CKD. Decreased
GFR and CKD estimated by CG were associated with
increased BMI and overweight/obesity.
Age and sex adjusted predictors of albuminuria,
decreased GFR and CKD
Age and sex adjusted predictors of albuminuria, de-
creased GFR and CKD are presented in Tables 4 and 5
separately for each of the estimators. Advanced age was
consistently and positively associated with all these out-
comes, with the magnitude of the effects per year in-
crease in age being 4 % (95%CI: 1–7 %) for albuminuria,
11 % (7–16 %) to 17 % (11–23 %) for decreased GFR,
and 6 % (4–9 %) to 9 % (7–12 %) for CKD. With the
exception of decreased GFR and CKD estimated by the
CG estimator, known hypertension status was also
significantly and positively associated with all the
outcomes; meanwhile existing diabetes was borderline
associated with albuminuria [OR 3.05 (95%CI: 0.98–
12.8), p = 0.055], and CKD based on MDRD [3.22 (0.99–
10.45), p = 0.051] and CKD-EPI [3.36 (1.02–11.07), p =
0.046] equations. Increasing BMI was significantly and
negatively associated with CG-defined decreased GFR and
CKD, and positively with MDRD and CKD-EPI defined de-
creased GFR, but not CKD. As a consequence, overweight/
obesity was associated with lower odd of CG defined
decreased GFR [0.11 (0.05–0.26), p < 0.001] and CKD [0.30
(0.17–0.54), p < 0.001]. The small number of outcomes
precluded expanded multivariable regression analysis.
Discussion
Our study assessed the prevalence and correlates of
CKD in an urban adults Cameroonian population using
the commonest estimators of kidney function. It re-
vealed a high frequency of CKD and related risk factors
in this population, with over one in ten participants hav-
ing CKD regardless of whether CG, MDRD or CKD-EPI
equations were used to estimate kidney function. This
high prevalence of CKD appeared to be driven mostly by
advanced age, hypertension, diabetes mellitus and adiposity.
Our study met the criteria of high quality applied in the
meta-analysis by Stanifer et al., and revealed a higher
prevalence of CKD in this setting, regardless the estima-
tors used, in line with the findings of the meta-analysis
and previous studies in Central and Western Africa region
[9, 11, 14]. These results confirm the already suggested
high burden of CKD in SSA setting. CKD prevalence rates
in our setting approximate those reported in other low-to-
middle income countries and implies that CKD is not af-
fecting only high-income countries [22–25]. Furthermore,
much higher prevalence rates have been reported in high
risk groups such as hypertensive, diabetes, obese and HIV
infected patients in SSA, inviting targeted and proactive
screening of these patients [10]. However, lower
prevalence rates have been observed in a country like
Senegal, in spite of similar high frequency of CKD risk
factors [4]. The discrepancy could be explained by the
differences in CKD definition used as well as methods for
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Table 1 Baseline characteristics, kidney function test and urine profile by sex
Characteristics Overall Men Women P
n (%) 500 (100) 267 (53.4) 233 (46.6) -
Mean age, years (SD) 45.3 (13.2) 45.9 (13.5) 44.6 (12.8) 0.267
History of hypertension (%) 61 (12.2) 25 (9.4) 36 (15.5) 0.041
History of diabetes (%) 14 (2.8) 6 (2.2) 8 (3.4) 0.433
History of gout (%) 6 (1.2) 4 (1.5) 2 (0.9) 0.690
Tobacco use currently or formerly (%) 35 (7.0) 34 (12.7) 1 (0.4) <0.001
Alcohol use currently or formerly (%) 272 (54.4) 184 (68.9) 88 (37.8) <0.001
Longstanding use of herbal medicine (%) 289 (57.8) 160 (59.9) 129 (55.4) 0.303
Longstanding use of street medicine (%) 148 (29.6) 81 (30.3) 67 (28.8) 0.768
Mean SBP, mmHg (SD) 132 (24) 137 (23) 128 (24) <0.001
Mean DBP, mmHg (SD) 81 (15) 82 (15) 81 (14) 0.267
Any hypertension (%) 193 (38.6) 109 (40.8) 84 (36.1) 0.311
Mean BMI, kg/m2 (SD) 27.1 (5.3) 25.8 (3.9) 28.6 (6.3) <0.001
BMI > 25 (%) 302 (60.4) 143 (53.6) 159 (68.2) 0.001
Pulse (SD) 77 (13) 74 (13) 79 (12) <0.001
Dipstick abnormalities (%)
Albuminuria 0.542
A1 464 (92.8) 246 (92.1) 218 (93.6)
A2 29 (5.8) 18 (6.7) 11 (4.7)
A3 7 (1.4) 3 (0.6) 4 (0.8)
Mean serum creatinine (jaffe), mg/dl (SD) 10.5 (2.6) 11.7 (2.6) 9.1 (1.8) <0.001
Mean serum creatinine (standardized), mg/dl (SD) 9.9 (2.5) 11.0 (2.5) 8.6 (1.7) <0.001
Mean Creatinine clearance, ml/min (SD)
MDRD 93.7 (24.9) 93.8 (25.3) 93.7 (24.5) 0.981
CG 97.8 (24.9) 96.5 (24.8) 99.4 (24.9) 0.201
CKD-EPI 99.2 (31.4) 95.5 (28.6) 103.5 (33.9) 0.005
Stages of kidney function (eGFR), (%)
MDRD >90 259 (51.8) 139 (52.1) 120 (51.5) 0.983
60–90 214 (42.8) 114 (42.7) 100 (42.9)
45–59 24 (4.8) 11 (4.1) 13 (5.6)
30–44 2 (0.4) 2 (0.7) 0 (0.0)
15–29 1 (0.2) 1 (0.3) 0 (0.0)
CG >90 296 (59.2) 155 (58.1) 141 (60.5) 0.854
60–90 160 (32.0) 88 (33.0) 72 (30.9)
45–59 33 (6.6) 16 (6.0) 17 (7.3)
30–44 10 (2.0) 7 (2.6) 3 (1.3)
15–29 1 (0.2) 1 (0.4) 0 (0.0)
CKD-EPI >90 301 (60.2) 152 (56.9) 149 (63.9) 0.206
60–90 177 (35.4) 104 (39.0) 73 (31.3)
45–59 19 (3.8) 8 (3.0) 11 (4.7)
30–44 2 (0.4) 2 (0.7) 0 (0.0)
15–29 1 (0.2) 1 (0.3) 0 (0.0)
A albuminuria, BMI body mass index, CG Cockroft-Gault, CKD-EPI chronic kidney disease epidemiology collaboration, DBP diastolic blood pressure, eGFR estimated
glomerular filtration rate, MDRD Modification of Diet in Renal Disease, SBP systolic blood pressure, SD standard deviation
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Table 2 Baseline characteristics by status for albuminuria and decreased GFR based on various kidney function estimators
Variables Albuminuria eGFR < 60 (MDRD) eGFR < 60 (CG) eGFR < 60 (CKD-EPI)
No Yes P No Yes P No Yes p No Yes p
n (%) 464 (92.8) 36 (7.2) 473 (94.6) 27 (5.4) 456 (91.2) 44 (8.8) 478 (95.6) 22 (4.4)
Sex (women) 218 (47.0) 15 (41.7) 0.605 220 (46.5) 13 (48.1) >0.999 213 (46.7) 20 (45.5) >0.999 222 (46.4) 11 (50.0) 0.828
Mean age, years (SD) 44.8 (13.0) 52.0 (14.1) 0.002 44.4 (12.7) 61.4 (10.9) <0.001 43.6 (12.1) 62.9 (11.1) <0.001 44.3 (12.6) 66.0 (9.1) <0.001
History of HTA (%) 50 (10.8) 11 (30.6) 0.002 49 (10.4) 12 (44.4) <0.001 48 (10.5) 13 (29.5) 0.001 49 (10.3) 12 (54.5) <0.001
History of diabetes (%) 10 (2.2) 4 (11.1) 0.014 10 (2.1) 4 (14.8) 0.005 10 (2.2) 4 (9.1) 0.027 10 (2.1) 4 (18.2) 0.002
History of goutte (%) 4 (0.9) 2 (5.6) 0.063 6 (1.3) 0 >0.999 6 (1.3) 0 >0.999 6 (1.3) 0 >0.999
Tobacco use (%) 33 (7.1) 2 (5.6) >0.999 34 (7.2) 1 (3.7) 0.711 34 (7.5) 1 (2.3) 0.348 35 (7.3) 0 0.389
Alcohol use (%) 255 (55.0) 17 (47.2) 0.390 259 (54.8) 13 (48.1) 0.554 253 (55.5) 19 (43.2) 0.153 262 (54.8) 10 (2.0) 0.512
Longstanding use of herbal medicine (%) 268 (57.8) 21 (58.3) >0.999 271 (57.3) 18 (66.7) 0.424 264 (57.9) 25 (56.8) >0.999 275 (57.5) 14 (63.6) 0.662
Longstanding use of street medicine (%) 133 (28.7) 15 (41.7) 0.128 143 (30.2) 5 (18.5) 0.278 135 (29.6) 31 (29.5) >0.999 142 (29.7) 6 (27.3) >0.999
Mean SBP, mmHg (SD) 132 (23) 138 (32) 0.199 132 (24) 142 (31) 0.033 131 (23) 144 (32) 0.001 132 (24) 145 (33) 0.011
Mean DBP, mmHg (SD) 81 (14) 85 (22) 0.094 81 (14) 86 (22) 0.074 81 (14) 84 (19) 0.168 81 (14) 86 (22) 0.136
Any hypertension (%) 174 (37.5) 19 (52.8) 0.077 174 (36.8) 19 (70.4) 0.001 166 (36.4) 27 (61.4) 0.002 176 (36.8) 17 (77.3) <0.001
Mean BMI, kg/m2 (SD) 27.1 (5.3) 27.4 (5.8) 0.712 27.0 (5.2) 29.0 (7.0) 0.055 27.4 (5.3) 23.4 (3.5) <0.001 27.0 (5.2) 28.5 (7.2) 0.200
BMI > =25 (%) 280 (60.3) 22 (61.1) >0.999 284 (60.0) 18 (66.7) 0.549 287 (62.9) 15 (34.1) <0.001 289 (60.5) 13 (59.1) >0.999
Pulse (SD) 76 (12) 81 (14) 0.043 76.5 (12.6) 77.6 (14.9) 0.670 77 (13) 76 (14) 0.887 76 (13) 79 (16) 0.448
BMI body mass index, CG cockroft-Gault, CKD-EPI chronic kidney disease epidemiology collaboration, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, MDRD Modification of Diet in Renal Disease,












assessing urinary albumin excretion and serum creatinine.
The reported higher prevalence rate of CKD could be
explained by the epidemiological transition; there is a dual
burden of diseases in this setting characterized by the
growing prevalence and the lower awareness, treatment
adherence and control rates of non-communicable
diseases, and the increase nephrotoxicity of drugs used in
the treatment of communicable disease [1, 4, 11, 26–28].
Across estimators of GFR, the CG equation diagnosed
more participants with decreased GFR and CKD while
Table 3 Baseline characteristics by status for chronic kidney disease based on various kidney function estimators
Variables CKD (MDRD) CKD (CKD-CG) CKD (CKD-EPI)
No Yes P No Yes p No Yes p
n (%) 445 (89.0) 55 (11.0) 429 (85.8) 71 (14.2) 450 (90.0) 50 (10.0)
Sex (women) 208 (46.7) 25 (45.5) 0.887 201 (46.9) 32 (46.6) 0.799 210 (46.7) 23 (46.0) >0.999
Mean age, years (SD) 44.1 (12.7) 54.7 (13.4) <0.001 43.4 (12.1) 56.9 (13.6) <0.001 44.1 (12.4) 56.1 (14.2) <0.001
History of hypertension (%) 44 (9.9) 17 (30.9) <0.001 42 (9.8) 19 (26.8) <0.001 44 (9.8) 17 (34.0) <0.001
History of diabetes (%) 8 (1.8) 6 (10.9) 0.002 8 (1.9) 6 (8.5) 0.008 8 (1.8) 6 (12.0) 0.001
History of gout (%) 4 (0.9) 2 (3.6) 0.134 4 (0.9) 2 (2.8) 0.204 4 (0.9) 2 (4.0) 0.113
Tobacco use (%) 32 (7.2) 3 (5.5) 0.785 32 (7.5) 3 (4.2) 0.453 33 (7.3) 2 (4.0) 0.561
Alcohol use (%) 245 (55.1) 27 (49.1) 0.473 238 (55.5) 34 (47.9) 0.249 248 (55.1) 24 (48.0) 0.371
Longstanding use of herbal medicine (%) 256 (57.5) 33 (60.0) 0.774 249 (58.0) 40 (56.3) 0.797 260 (57.8) 29 (58.0) >0.999
Longstanding use of street medicine (%) 130 (29.2) 18 (32.7) 0.639 124 (28.9) 24 (33.8) 0.403 129 (28.7) 19 (38.0) 0.192
Mean SBP, mmHg (SD) 132 (24) 138 (29) 0.081 131 (23) 140 (30) 0.008 132 (24) 139 (30) 0.052
Mean DBP, mmHg (SD) 81 (14) 85 (19) 0.076 81 (14) 94 (18) 0.138 81 (14) 84 (19) 0.127
Any hypertension (%) 161 (36.2) 32 (58.2) 0.002 154 (35.9) 39 (54.9) 0.004 163 (36.2) 30 (60.0) 0.002
Mean BMI, kg/m2 (SD) 27.0 (12.6) 28.2 (6.5) 0.107 27.4 (5.3) 25.2 (5.1) 0.002 27.0 (5.2) 27.9 (6.5) 0.268
BMI > =25 (%) 267 (60.0) 35 (63.6) 0.663 269 (62.7) 33 (46.5) 0.012 272 (60.4) 30 (60.0) >0.999
Pulse (SD) 76 (13) 78 (14) 0.344 76 (13) 77 (13) 0.651 76 (13) 79 (14) 0.236
BMI body mass index, CG Cockroft-Gault, CKD chronic kidney disease, CKD-EPI chronic kidney disease epidemiology collaboration, DBP diastolic blood pressure,
MDRD Modification of Diet in Renal Disease, SBP systolic blood pressure, SD standard deviation
Table 4 Predictors of albuminuria and decreased GFR in age and sex adjusted logistic regressions
Variables Albuminuria eGFR < 60 (MDRD) eGFR < 60 (CG) eGFR < 60 (CKD-EPI)
OR (95 % CI) p OR (95 % CI) p OR (95 % CI) p OR (95 % CI) p
Sex (women) 0.86 (0.43–1.72) 0.661 0.75 (0.33–1.75) 0.512 0.81 (0.39–1.69) 0.575 0.61 (0.23–1.64) 0.325
Age, per years 1.04 (1.01–1.07) 0.002 1.11 (1.07–1.16) <0.001 1.16 (1.11–1.20) <0.001 1.17 (1.11–1.23) <0.001
History of hypertension 2.70 (1.18–6.17) 0.019 3.42 (1.41–8.28) 0.007 1.40 (0.61–3.22) 0.422 5.93 (2.06–17.05) 0.001
History of diabetes 3.05 (0.98–12.8) 0.055 2.59 (0.63–10.56) 0.184 1.02 (0.23–4.52) 0.974 2.88 (0.61–13.54) 0.180
History of gout 6.17 (1.07–35.61) 0.042 ≅0 0.999 ≅0 0.999 ≅0 0.999
Tobacco use 0.70 (0.15–3.15) 0.642 0.65 (0.08–5.51) 0.695 0.33 (0.04–2.95) 0.324 ≅0 0.998
Alcohol use 0.58 (0.28–1.22) 0.152 1.29 (0.51–3.26) 0.584 2.19 (0.96–4.96) 0.061 1.18 (0.39–3.59) 0.771
Longstanding use of herbal medicine 1.01 (0.50–2.03) 0970 1.67 (0.6904.03) 0.256 1.03 (0.50–2.15) 0.930 1.50 (0.54–4.15) 0.432
Longstanding use of street medicine 1.65 (0.82–3.33) 0.162 0.40 (0.14–1.15) 0.089 0.74 (0.34–1.64) 0.464 0.70 (0.24–2.06) 0.517
SBP, mmHg 1.00 (0.99–1.01) 0.894 1.01 (0.99–1.02) 0.881 1.00 (0.99–1.02) 0.675 1.00 (0.99–1.02) 0.640
DBP, mmHg 1.01 (0.99–1.03) 0.367 1.01 (0.98–1.03) 0.494 1.00 (0.97–1.02) 0.716 1.01 (0.98–1.04) 0.576
Any hypertension 1.28 (0.62–2.67) 0.506 1.85 (0.74–4.60) 0.185 0.97 (0.45–2.08) 0.942 2.48 (0.80–7.68) 0.116
BMI, per kg/m2 1.01 (0.94–1.08) 0.773 1.09 (1.01–1.18) 0.032 0.71 (0.62–0.81) <0.001 1.10 (1.00–1.20) 0.055
BMI > =25 0.89 (0.43–1.83) 0.754 1.09 (0.43–2.74) 0.855 0.11 (0.05–0.26) <0.001 0.72 (0.25–2.08) 0.544
Pulse 1.03 (1.00–1.05) 0.048 1.00 (0.97–1.04) 0.802 0.99 (0.96–1.02) 0.574 1.01 (0.98–1.05) 0.477
BMI body mass index, CG Cockroft-Gault, CKD-EPI chronic kidney disease epidemiology collaboration, DBP diastolic blood pressure, eGFR estimated glomerular fil-
tration rate, MDRD Modification of Diet in Renal Disease, SBP systolic blood pressure, SD standard deviation
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CKD-EPI and MDRD with ethnicity correction diag-
nosed about the same proportion of participants with
both conditions, largely in line with existing and exten-
sively discussed reports from previous studies [11, 13,
14]. The observed higher GFR estimated by CKD-EPI
equation compared to others estimators could be related
to the fact that this equation performed better than
others especially at higher GFR [17, 18].
Regardless of the estimators used to assess CKD,
advanced age, hypertension, diabetes mellitus and adiposity
were the risk factors of CKD observed in this study as
reported elsewhere [4, 11–13]. These are well known
clinical and socio-demographic risk factors for CKD occur-
rence and progression to end stage renal disease (ESRD)
[19]. Moreover, hypertension and diabetes mellitus are
associated with glomerular diseases and constitute the main
etiological factors for CKD in SSA [5, 6]. These findings
invite appropriate management of such factors and an array
of actions to tackle them as well as implementation of
sensitization campaign to raise awareness, increase treat-
ment adherence and improve control rate. This is import-
ant to reduce the growing prevalence of ESRD patients in
this lower middle income country where social security
programs are inexistent, and where patients with CKD are
referred late to nephrologists [29, 30]. Furthermore, in
Cameroon for instance, and in spite of government’s
subsidies, patients with ESRD on renal replacement therapy
must pay the equivalent of US$ 12 per dialysis session
[US$ 1248 per annum, which is almost the gross na-
tional income per capita of US$ 1270 in 2013] in
addition to the costs of caring for comorbidities [29–31].
Strengths and limitations
The present study has some limitations including the
semi-quantitative assessment of urinary albumin excre-
tion using dipsticks, the non-validation of any of the
equations used in SSA populations and the lack of three
months control of positive findings to confirm the
chronicity of renal injury as recommended by the
KDIGO guidelines [19]. However, previous studies from
Ghana and South Africa have found a high agreement
between ethnicity corrected MDRD and CKD-EPI
equations, supporting their use in this setting [13, 14].
Moreover, by conducting this study in only one urban
health district of the country, there is little opportunity
of assessing variations in the prevalence of CKD across
the gradient of urbanization in the country. Lastly, the
study was likely underpowered to reliably investigate the
determinants of the disease. However, this study to our
knowledge is the first to use a multistage cluster sampling
to provide community-based data on the epidemiology of
kidney disease in the country with the three estimators of
kidney function. The inclusion of participants from a
cosmopolite urban health district likely captures the diver-
sity of the national population with our results likely
reflecting the national urban prevalence of CKD.
Conclusions
This study revealed that more than one in ten partici-
pants presented with CKD regardless the estimators
used. This sizable prevalence of CKD, similar to those
reported in developed countries, is driven essentially by
the well-known clinical and socio-demographic risk
Table 5 Predictors of chronic kidney disease in age and sex adjusted logistic regressions
Variables CKD (MDRD) CKD (CG) CKD (CKD-EPI)
OR (95 % CI) p OR (95 % CI) p OR (95 % CI) p
Sex (women) 1.05 (0.59–1.89) 0.856 1.07 (0.62–1.87) 0.805 1.10 (0.59–2.04) 0.759
Age, per years 1.06 (1.04–1.09) <0.001 1.09 (1.07–1.12) <0.001 1.08 (1.05–1.10) <0.001
History of HTA 2.40 (1.19–4.82) 0.014 1.61 (0.82–3.16) 0.164 2.66 (1.30–5.41) 0.007
History of diabetes 3.22 (0.99–10.45) 0.051 1.79 (0.53–5.99) 0.348 3.36 (1.02–11.07) 0.046
History of gout 3.95 (0.68–23.01) 0.126 3.02 (0.50–18.01) 0.226 4.62 (0.78–27.27) 0.091
Tobacco use 0.76 (0.21–2.70) 0.670 0.55 (0.15–2.00) 0.366 0.55 (0.12–2.48) 0.432
Alcohol use 0.65 (0.35–1.23) 0.188 0.56 (0.31–1.02) 0.060 0.63 (0.32–1.22) 0.171
Longstanding use of herbal medicine 1.12 (0.62–2.04) 0.699 0.94 (0.54–1.64) 0.838 1.03 (0.55–1.91) 0.934
Longstanding use of street medicine 1.05 (0.56–1.96) 0.879 1.09 (0.61–1.94) 0.778 1.38 (0.73–2.60) 0.325
SBP, mmHg 1.00 (0.99–1.01) 0.864 1.00 (0.99–1.01) 0.888 1.00 (0.99–1.01) 0.916
DBP, mmHg 1.00 (0.99–1.02) 0.616 1.00 (0.98–1.01) 0.720 1.00 (0.98–1.02) 0.849
Any hypertension 1.44 (0.77–2.66) 0.249 1.01 (0.57–1.80) 0.964 1.44 (0.75–2.76) 0.269
BMI, per kg/m2 1.04 (0.98–1.10) 0.170 0.88 (0.82–0.94) <0.001 1.03 (0.97–1.09) 0.384
BMI > =25 0.92 (0.49–1.71) 0.797 0.30 (0.17–0.54) <0.001 0.74 (0.39–1.42) 0.364
Pulse 1.01 (0.99–1.03) 0.440 1.00 (0.98–1.02) 0.872 1.01 (0.99–1.04) 0.308
BMI body mass index, CG Cockroft-Gault, CKD chronic kidney disease, CKD-EPI chronic kidney disease epidemiology collaboration, DBP diastolic blood pressure,
MDRD Modification of Diet in Renal Disease, SBP systolic blood pressure, SD standard deviation
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factors for CKD. Actions are needed both to prevent
further increase in the prevalence of CKD and to
improve the detection and appropriate management of
those with risk factors of the disease.
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